AERI Aerie Pharmaceuticals, Inc.

Healthcare [ 2/11 ] | Drug Manufacturers—Specialty & Generic [ 24/154 ]

US | NASDAQ | Stock

Price: $15.25

Increased by 0.00%
Dollar Volume: 7.90 M
ADR%: 0.14
Earnings Report Date (estimate): Feb 22, 23 (N/A)

Market Cap.: 753.62 M
Shares Float: 43.85 M
Shares Outstanding: 49.39 M

Beta: -0.06
Price / Earnings: -10.36
BPR: 471.86

20D Range: 15.17 15.25
50D Range: 15.04 15.26
200D Range: 4.81 15.37

Quarterly Earnings
Annual Earnings

Reported Date	EPSChange YoY	EstimateSurprise
Nov 3, 22	-0.27 Decreased by -124.77%	-0.44 Increased by +38.64%
Aug 4, 22	-0.32 Increased by +55.56%	-0.56 Increased by +42.86%
May 5, 22	-0.66 Increased by +1.49%	-0.65 Decreased by -1.54%
Feb 24, 22	1.09 Increased by +251.39%	-0.67 Increased by +262.69%
Feb 23, 22	1.09 Increased by +237.97%	-0.67 Increased by +262.69%
Nov 4, 21	-0.72 Decreased by -10.77%	-0.62 Decreased by -16.13%
Aug 4, 21	-0.67 Increased by +19.28%	-0.64 Decreased by -4.69%
May 5, 21	-0.72 Increased by +13.25%	-0.68 Decreased by -5.88%

Quarterly Financials
Annual Financials

Fiscal ending date	RevenueChange YoY	IncomeChange YoY	ProfitChange YoY
Sep 30, 22	36.13 M Increased by +23.25%	-26.83 M Increased by +32.41%	Decreased by -74.25% Increased by +45.16%
Jun 30, 22	33.31 M Increased by +22.53%	-19.37 M Increased by +49.93%	Decreased by -58.15% Increased by +59.14%
Mar 31, 22	29.84 M Increased by +29.89%	-35.89 M Increased by +14.47%	Decreased by -120.30% Increased by +34.15%
Dec 31, 21	114.67 M Increased by +364.55%	45.53 M Increased by +198.69%	Increased by +39.71% Increased by +121.24%
Sep 30, 21	29.31 M Increased by +45.97%	-39.69 M Decreased by -0.11%	Decreased by -135.40% Increased by +31.42%
Jun 30, 21	27.18 M Increased by +50.75%	-38.69 M Increased by +19.71%	Decreased by -142.31% Increased by +46.74%
Mar 31, 21	22.97 M Increased by +12.92%	-41.96 M Increased by +14.58%	Decreased by -182.69% Increased by +24.36%
Dec 31, 20	24.68 M Increased by +0.11%	-46.14 M Increased by +16.21%	Decreased by -186.92% Increased by +16.30%

Top 20 ETF Stock Exposure
Top 20 Institutional Holders
Top 20 Mutual Fund Holders

Rank	ETF	Shares	Market Value	Weight % in ETF

DAILY

WEEKLY

MONTHLY

Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.